---
title: "BrightGene Bio-Medical Technology Co.,Ltd. (688166.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688166.SH.md"
symbol: "688166.SH"
name: "BrightGene Bio-Medical Technology Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T07:45:38.929Z"
locales:
  - [en](https://longbridge.com/en/quote/688166.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688166.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688166.SH.md)
---

# BrightGene Bio-Medical Technology Co.,Ltd. (688166.SH)

## Company Overview

BrightGene Bio-Medical Technology Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products in China and internationally. The company develops BGM0504 injection, which is in Phase III clinical trial for treatment of type 2 diabetes and weight loss; and BGM1812, a long-acting amylin analog in preclinical development. It also provides formulations; preparation products; active pharmaceutical ingredients and intermediates; and veterinary drugs for various therapeutic areas, including metabolism, oncology, respiratory, immunosuppression, antiviral, antifungal, antitumor, cerebrovascular, iron supplement, antibodies drug conjugate, anti-infection, angiography, gynecology, cardiovascular, digestion, and others. In addition, the company is involved in technology research and development; transfer of biomedical products; import, export, wholesale, and retail of medicines; production and operation of medical devices; and technical services.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.bright-gene.com](https://www.bright-gene.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.51)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 74 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 9.09% |  |
| Net Profit YoY | -63.17% |  |
| P/B Ratio | 10.61 |  |
| Dividend Ratio | 0.15% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 26235993444.96 |  |
| Revenue | 1301926668.43 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 2.02% | C |
| Profit Margin | 3.91% | C |
| Gross Margin | 56.77% | B |
| Revenue YoY | 9.09% | B |
| Net Profit YoY | -63.17% | D |
| Total Assets YoY | 23.65% | A |
| Net Assets YoY | 10.92% | B |
| Cash Flow Margin | 210.30% | B |
| OCF YoY | 9.09% | B |
| Turnover | 0.22 | D |
| Gearing Ratio | 55.60% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - BrightGene Bio-Medical Technology Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "9.09%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.17%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "10.61",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.15%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "26235993444.96",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1301926668.43",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "2.02%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "3.91%",
          "rating": "C"
        },
        {
          "name": "Gross Margin",
          "value": "56.77%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "9.09%",
          "rating": "B"
        },
        {
          "name": "Net Profit YoY",
          "value": "-63.17%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "23.65%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "10.92%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "210.30%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "9.09%",
          "rating": "B"
        },
        {
          "name": "Turnover",
          "value": "0.22",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "55.60%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 515.05 | 164/215 | 384.34 | 335.32 | 230.61 |
| PB | 10.61 | 212/215 | 11.75 | 9.46 | 8.62 |
| PS (TTM) | 20.15 | 209/215 | 24.16 | 19.15 | 17.43 |
| Dividend Yield | 0.15% | 151/215 | 0.20% | 0.18% | 0.14% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-07T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 56.28 |
| Highest Target | 38.00 |
| Lowest Target | 38.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688166.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688166.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688166.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/688166.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**